SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
-------------
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) January 7, 2000
---------------
RIBOZYME PHARMACEUTICALS, INC.
- -------------------------------------------------------------------------------
(Exact name of registrant as specified in charter)
Colorado 0-27914 34-1697351
- --------------------------------------------------------------------------------
(State or other (Commission (IRS employer
jurisdiction of file number) identification no.)
incorporation
or organization)
2950 Wilderness Place, Boulder, Colorado 80301
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (303) 449-6500
--------------
N/A
- --------------------------------------------------------------------------------
(Former name or former address, if changed since last report.)
5. Other Events
The Form 8-K filed by Ribozyme Pharmaceuticals, Inc. (the "Company") on
February 8, 2000, is incorporated herein by reference.
-2-
EXHIBITS
1.+ Securities Purchase Agreement dated January 7, 2000, among the
Company, Elan International Services, Ltd. and Elan Corporation, plc
2* License Agreement dated January 7, 2000, among Elan Pharmaceutical
Technologies (a division of Elan Corporation, plc), Elan Pharma
International Limited and Medizyme Pharmaceuticals Ltd.
3.+ Warrant dated January 7, 2000, issued to Elan International Services,
Ltd. to purchase up to 200,000 shares of the Company's common stock
4.+ Warrant dated January 7, 2000, issued to Elan International Services,
Ltd. to purchase up to 300,000 shares of the Company's common stock
5.+ Convertible Promissory Note dated January 7, 2000, from the Company to
Elan International Services, Ltd.
6* Subscription, Joint Development and Operating Agreement dated January
7, 2000, among the Company, Elan Corporation, plc, Elan Pharma
International Limited, Elan International Services, Ltd. and Medizyme
Pharmaceuticals Ltd.
-3-
7.+ Funding Agreement dated January 7, 2000, among the Company, Elan
Pharmaceutical Technologies (a division of Elan Corporation, plc),
Elan Pharma International Limited and Elan International Services,
Ltd.
8* License Agreement dated January 7, 2000, between the Company and
Medizyme Pharmaceuticals Ltd.
9.+ Registration Rights Agreement dated January 7, 2000, between the
Company and Elan International Services, Ltd.
10.+ Registration Rights Agreement dated January 7, 2000, among the
Company, Elan International Services, Ltd. and Medizyme
Pharmaceuticals Ltd.
11.+ Certificate of Designations, Preferences and Rights of Series A
Preferred Stock and Series B Preferred Stock of the Company
12.+* Agreement dated January 31, 2000, between the Company and Avecia
Limited.
*Confidential treatment has been requested for portions of these agreements.
+Previously filed.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
RIBOZYME PHARMACEUTICALS, INC.
DATE: March 2, 2000 By: /s/ Dr. Ralph E. Christoffersen
-------------------------------------------
Dr. Ralph E. Christoffersen, President
-4-